Physician profile
Robert W Inzer
NPI 1497780118
$13,220.24
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,250 · 2020: $1,885 · 2021: $3,064 · 2022: $15.34 · 2023: $6.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $11,532.40 | 2019-2021 | |
| Abbvie INC. | $593.66 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $181.98 | 2019 | |
| Pfizer INC. | $101.58 | 2019-2020 | |
| Therapeuticsmd, INC. | $97.41 | 2019-2021 | |
| Allergan, INC. | $89.60 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $88.33 | 2019-2020 | |
| Millicent US INC | $82.45 | 2020 | |
| Coopersurgical, INC. | $60.24 | 2019-2020 | |
| Ethicon US, LLC | $58.28 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $56.23 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $42.74 | 2019 | |
| Duchesnay USA Incorporated | $42.71 | 2019 | |
| Lupin INC. | $40.94 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $21.90 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mission Pharmacal Company | $20.08 | 2021 | |
| Minerva Surgical, INC | $19.88 | 2021 | |
| Agile Therapeutics, INC. | $16.07 | 2021 | |
| Exeltis, USA INC. | $14.71 | 2021 | |
| Covidien LP | $14.50 | 2019 | |
| Acessa Health INC. | $14.40 | 2021 | |
| Avion Pharmaceuticals | $12.09 | 2021 | |
| Avanos Medical | $11.80 | 2019 | |
| Organon LLC | $6.26 | 2023 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Inzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.